General Information of the Protein
Protein ID
PT01065
Protein Name
Serine/threonine-protein kinase mTOR
Secondarily
Protein Name
FK506-binding protein 12-rapamycin complex-associated protein 1
FKBP12-rapamycin complex-associated protein
Mammalian target of rapamycin
Mechanistic target of rapamycin
Rapamycin and FKBP12 target 1
Rapamycin target protein 1
Gene Name
MTOR
Secondarily
Gene Name
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
Sequence
MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
Atypical protein kinase group
>
Atypical protein kinase PIKK family
>
Atypical protein kinase FRAP subfamily
Function
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals (PubMed:12087098, PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, PubMed:31112131, PubMed:31601708, PubMed:32561715, PubMed:34519269, PubMed:29236692, PubMed:37751742). MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins (PubMed:15268862, PubMed:15467718, PubMed:17517883, PubMed:18925875, PubMed:18372248, PubMed:18497260, PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, PubMed:29236692, PubMed:37751742). Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) (PubMed:15268862, PubMed:15467718, PubMed:18925875, PubMed:18497260, PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704). In response to nutrients, growth factors or amino acids, mTORC1 is recruited to the lysosome membrane and promotes protein, lipid and nucleotide synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, PubMed:31112131, PubMed:34519269, PubMed:29236692). This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E) (PubMed:24403073, PubMed:29236692). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4 (PubMed:12150925, PubMed:12087098, PubMed:18925875, PubMed:29150432, PubMed:29236692). Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex (PubMed:23429704, PubMed:23429703). Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor (PubMed:20516213). Activates dormant ribosomes by mediating phosphorylation of SERBP1, leading to SERBP1 inactivation and reactivation of translation (PubMed:36691768). In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1 (By similarity). To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A (By similarity). In the same time, mTORC1 inhibits catabolic pathways: negatively regulates autophagy through phosphorylation of ULK1 (PubMed:32561715). Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1 (PubMed:32561715). Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich conditions (PubMed:30704899). Prevents autophagy by mediating phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor (PubMed:21659604). Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). The mTORC1 complex is inhibited in response to starvation and amino acid depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073). The non-canonical mTORC1 complex, which acts independently of RHEB, specifically mediates phosphorylation of MiT/TFE factors MITF, TFEB and TFE3 in the presence of nutrients, promoting their cytosolic retention and inactivation (PubMed:22576015, PubMed:22343943, PubMed:22692423, PubMed:24448649, PubMed:32612235, PubMed:36608670, PubMed:36697823). Upon starvation or lysosomal stress, inhibition of mTORC1 induces dephosphorylation and nuclear translocation of TFEB and TFE3, promoting their transcription factor activity (PubMed:22576015, PubMed:22343943, PubMed:22692423, PubMed:24448649, PubMed:32612235, PubMed:36608670). The mTORC1 complex regulates pyroptosis in macrophages by promoting GSDMD oligomerization (PubMed:34289345). MTOR phosphorylates RPTOR which in turn inhibits mTORC1 (By similarity). As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton (PubMed:15268862, PubMed:15467718). mTORC2 plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1 (PubMed:15718470). mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B (PubMed:15268862). mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422' (PubMed:18925875). Regulates osteoclastogenesis by adjusting the expression of CEBPB isoforms (By similarity). Plays an important regulatory role in the circadian clock function; regulates period length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and liver clocks (By similarity). Phosphorylates SQSTM1, promoting interaction between SQSTM1 and KEAP1 and subsequent inactivation of the BCR(KEAP1) complex (By similarity).
    Show/Hide
Uniprot ID
Primary ID:
P42345

Secondarily ID:
Q4LE76
Q5TER1
Q6LE87
Q96QG3
Q9Y4I3
    Show/Hide
Ensembl ID
ENSG00000198793
HGNC ID
HGNC:3942
Subcellular Location
Lysosome membrane
Endoplasmic reticulum membrane
Golgi apparatus membrane
Mitochondrion outer membrane
Cytoplasm
Nucleus
Nucleus
PML body
Microsome membrane
Cytoplasmic vesicle
Phagosome
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000098 , A2058
Compound ID Compound Name Compound Formula
CP0013606
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
   Show/Hide
C17H20F3N7O2
 1
1
IC50 = 205 nM
   TI
   LI
   LO
   TS
CP0536937
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyrimidin-2-amine
   Show/Hide
C16H19F3N8O2
 1
1
IC50 = 312 nM
   TI
   LI
   LO
   TS
CP0456424
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)pyridin-2-amine
   Show/Hide
C16H21N7O2
 1
1
IC50 = 415 nM
   TI
   LI
   LO
   TS
CP0563000
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)pyrimidin-2-amine
   Show/Hide
C15H20N8O2
 1
1
IC50 = 415 nM
   TI
   LI
   LO
   TS
CP0454795
N-[5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl]acetamide
   Show/Hide
C19H22F3N7O3
 1
1
IC50 = 729 nM
   TI
   LI
   LO
   TS
CP0574318
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)pyrazin-2-amine
   Show/Hide
C15H20N8O2
 1
1
IC50 = 817 nM
   TI
   LI
   LO
   TS
CP0476128
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-methylpyrimidin-2-amine
   Show/Hide
C16H22N8O2
 1
1
IC50 = 831 nM
   TI
   LI
   LO
   TS
CP0454797
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-methylpyridin-2-amine
   Show/Hide
C17H23N7O2
 1
1
IC50 = 939 nM
   TI
   LI
   LO
   TS
CP0508404
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-3-methylpyridin-2-amine
   Show/Hide
C17H23N7O2
 1
1
IC50 = 1105 nM
   TI
   LI
   LO
   TS
CP0394871
4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline
   Show/Hide
C17H22N6O2
 1
1
IC50 = 1282 nM
   TI
   LI
   LO
   TS
CP0454796
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-3-(trifluoromethyl)pyridin-2-amine
   Show/Hide
C17H20F3N7O2
 1
1
IC50 = 1638 nM
   TI
   LI
   LO
   TS
CP0567096
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-N-methoxy-4-(trifluoromethyl)pyridin-2-amine
   Show/Hide
C18H22F3N7O3
 1
1
IC50 = 5588 nM
   TI
   LI
   LO
   TS
CP0562999
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-1H-pyridin-2-one
   Show/Hide
C17H19F3N6O3
 1
1
IC50 = 17000000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0140024
pyrazolo pyrimidine, 24
   Show/Hide
C28H31N9O4
 1
1 IC50 = 0.2 nM
CP0050330
5-(1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)benzene-1,3-diol
   Show/Hide
C17H15N7O2
 1
1 IC50 = 0.2 nM
CP0275509
1-(4-(4-morpholino-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)-3-(pyridin-3-yl)urea
   Show/Hide
C23H21F3N8O2
 1
1 IC50 = 0.23 nM
CP0166414
pyrazolo pyrimidine, 21
   Show/Hide
C25H32N8O4
 1
1 IC50 = 0.32 nM
CP0104068
pyrazolo pyrimidine, 10
   Show/Hide
C28H33N9O2
 1
1 IC50 = 0.38 nM
CP0000815
Rapamycin C-7, analog 4
   Show/Hide
C51H79NO13
 6
1 IC50 = 0.45 nM
2 IC50 = 0.8 nM
3 IC50 = 1.6 nM
4 IC50 = 3.467 nM
5 IC50 = 430 nM
6 Kd = 0.6 nM
CP0010884
pyrazolo pyrimidine, 18
   Show/Hide
C24H30N8O4
 1
1 IC50 = 0.46 nM
CP0150168
1-(2-fluoroethyl)-3-(4-(4-morpholino-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)urea
   Show/Hide
C20H21F4N7O2
 1
1 IC50 = 0.6 nM
CP0008552
AZD-8055
   Show/Hide
C25H31N5O4
 5
1 IC50 = 0.8 nM
2 IC50 = 4 nM
3 IC50 = 8 nM
4 IC50 = 8.9 nM
5 IC50 < 100 nM
CP0135942
1-methyl-3-(4-(4-morpholino-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)urea
   Show/Hide
C19H20F3N7O2
 1
1 IC50 = 1 nM
CP0002102
Afinitor
   Show/Hide
C53H83NO14
 2
1 IC50 = 1.6 nM
2 Kd = 2 nM
CP0050331
1-(4-(1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenyl)-3-methylurea
   Show/Hide
C19H19N9O
 1
1 IC50 = 2 nM
CP0079284
5-(2-amino-3H-benzimidazol-5-yl)-3-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2-one
   Show/Hide
C19H21N7O
 1
1 IC50 = 2 nM
CP0079286
3-(oxan-4-ylmethyl)-5-[4-(1H-1,2,4-triazol-5-yl)phenyl]-1H-imidazo[4,5-b]pyrazin-2-one
   Show/Hide
C19H19N7O2
 1
1 IC50 = 2 nM
CP0005305
AZD-2014
   Show/Hide
C25H30N6O3
 2
1 IC50 = 2.8 nM
2 IC50 = 20 nM
CP0007893
4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine
   Show/Hide
C23H27N7O3S2
 11
1 IC50 = 3 nM
2 IC50 = 310 nM
3 IC50 = 410 nM
4 IC50 = 580 nM
5 IC50 = 712 nM
6 IC50 = 959 nM
7 IC50 = 3351 nM
8 Kd = 48 nM
9 Kd = 200 nM
10 Ki = 570 nM
11 Ki = 580 nM
CP0022562
N-[5-(3-chloro-4-oxopyrido[1,2-a]pyrimidin-7-yl)-2-methoxypyridin-3-yl]-2,4-difluorobenzenesulfonamide
   Show/Hide
C20H13ClF2N4O4S
 1
1 IC50 = 4.7 nM
CP0016639
pyrazolo pyrimidine, 19
   Show/Hide
C24H29N7O5
 1
1 IC50 = 5 nM
CP0275534
5-[4-(1H-imidazol-2-yl)phenyl]-3-(oxan-4-ylmethyl)-1H-imidazo[4,5-b]pyrazin-2-one
   Show/Hide
C20H20N6O2
 1
1 IC50 = 5 nM
CP0152241
5-[2-(methylamino)-3H-benzimidazol-5-yl]-3-(oxan-4-ylmethyl)-1H-imidazo[4,5-b]pyrazin-2-one
   Show/Hide
C19H21N7O2
 1
1 IC50 = 6 nM
CP0204367
3-(1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C17H15N7O
 1
1 IC50 = 7 nM
CP0142914
2-(4-(2-(3-hydroxyphenylamino)-1H-benzo[d]imidazol-1-yl)-6-methyl-1,3,5-triazin-2-ylamino)acetonitrile
   Show/Hide
C19H16N8O
 1
1 IC50 = 8 nM
CP0303029
JMC527081 Compound 5f
   Show/Hide
C26H29N7O2
 1
1 IC50 = 10 nM
CP0007454
(5-(2-((2R,6S)-2,6-dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
   Show/Hide
C25H31N5O4
 1
1 IC50 = 10 nM
CP0075071
N-[4-[[1-(4-amino-6-methyl-1,3,5-triazin-2-yl)benzimidazol-2-yl]amino]phenyl]acetamide
   Show/Hide
C19H18N8O
 1
1 IC50 = 13 nM
CP0210024
4-[4-(2-methylimidazol-1-yl)-6-(7-methyl-1H-indol-4-yl)-1,3,5-triazin-2-yl]morpholine
   Show/Hide
C20H21N7O
 1
1 IC50 = 18 nM
CP0540714
2,4-difluoro-N-[2-methoxy-5-(4-oxopyrido[1,2-a]pyrimidin-7-yl)pyridin-3-yl]benzenesulfonamide
   Show/Hide
C20H14F2N4O4S
 1
1 IC50 = 19.2 nM
CP0238827
3-(1-(4-amino-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C16H13N7O
 1
1 IC50 = 21 nM
CP0076228
5-(3H-benzimidazol-5-yl)-3-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2-one
   Show/Hide
C19H20N6O
 1
1 IC50 = 21 nM
CP0275536
5-(1H-indol-5-yl)-3-(oxan-4-ylmethyl)-1H-imidazo[4,5-b]pyrazin-2-one
   Show/Hide
C19H19N5O2
 1
1 IC50 = 21 nM
CP0050328
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1H-pyrazol-3-yl)-1H-benzimidazol-2-amine
   Show/Hide
C14H13N9
 2
1 IC50 = 23 nM
2 IC50 = 27 nM
CP0204366
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-5,6-difluoro-N-(1H-pyrazol-3-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C14H11F2N9
 1
1 IC50 = 24 nM
CP0081060
4-[4-(2-ethylimidazol-1-yl)-6-(1H-indol-4-yl)-1,3,5-triazin-2-yl]morpholine
   Show/Hide
C20H21N7O
 1
1 IC50 = 26 nM
CP0287661
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1H-indazol-6-yl)benzimidazol-2-amine
   Show/Hide
C18H15N9
 1
1 IC50 = 27 nM
CP0075072
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1H-indol-6-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C19H16N8
 1
1 IC50 = 28 nM
CP0087145
3-(cyclohexylmethyl)-5-[4-(2-hydroxypropan-2-yl)phenyl]-1H-imidazo[4,5-b]pyrazin-2-one
   Show/Hide
C21H26N4O2
 1
1 IC50 = 30 nM
CP0160473
2-(4-(2-(1H-pyrazol-3-ylamino)-1H-benzo[d]imidazol-1-yl)-6-methyl-1,3,5-triazin-2-ylamino)acetonitrile
   Show/Hide
C16H14N10
 1
1 IC50 = 31 nM
CP0068244
(3R)-3-methyl-4-[6-(1-methylsulfonylcyclopropyl)-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)pyrimidin-4-yl]morpholine
   Show/Hide
C20H23N5O3S
 1
1 IC50 = 34 nM
CP0068243
(3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)pyrimidin-4-yl]-3-methylmorpholine
   Show/Hide
C21H24N4O3S
 1
1 IC50 = 38 nM
CP0068245
N-methyl-1-[4-[(3R)-3-methylmorpholin-4-yl]-6-(1-methylsulfonylcyclopropyl)pyrimidin-2-yl]benzimidazol-2-amine
   Show/Hide
C21H26N6O3S
 1
1 IC50 = 52 nM
CP0142925
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1H-indazol-3-yl)benzimidazol-2-amine
   Show/Hide
C18H15N9
 1
1 IC50 = 60 nM
CP0169966
3-(4-(2-(1H-pyrazol-3-ylamino)-1H-benzo[d]imidazol-1-yl)-6-methyl-1,3,5-triazin-2-ylamino)propanenitrile
   Show/Hide
C17H16N10
 1
1 IC50 = 60 nM
CP0081135
4-[4-[5-ethyl-3-(trifluoromethyl)pyrazol-1-yl]-6-(1H-indol-4-yl)-1,3,5-triazin-2-yl]morpholine
   Show/Hide
C21H20F3N7O
 1
1 IC50 = 71 nM
CP0282345
pyrazolo pyrimidine, 5e
   Show/Hide
C27H30N6O2
 1
1 IC50 = 78 nM
CP0137531
1-(4-methyl-6-(prop-2-ynylamino)-1,3,5-triazin-2-yl)-N-(1H-pyrazol-3-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C17H15N9
 1
1 IC50 = 80 nM
CP0050336
1-(4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)-N-(1H-pyrazol-3-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C15H15N9
 1
1 IC50 = 81 nM
CP0238828
3-(1-(6-amino-2-methylpyrimidin-4-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C18H16N6O
 1
1 IC50 = 87 nM
CP0013606
5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
   Show/Hide
C17H20F3N7O2
 1
1 IC50 = 89 nM
CP0050326
2-(4-(2-(3-hydroxyphenylamino)-1H-benzo[d]imidazol-1-yl)-1,3,5-triazin-2-ylamino)acetonitrile
   Show/Hide
C18H14N8O
 2
1 IC50 = 93 nM
2 IC50 = 97 nM
CP0345668
3-(1-(6-aminopyrimidin-4-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C17H14N6O
 1
1 IC50 = 110 nM
CP0038249
3-(9-(1-benzylpiperidin-4-yl)-6-morpholino-9H-purin-2-yl)phenol
   Show/Hide
C27H30N6O2
 1
1 IC50 = 140 nM
CP0137535
5-(1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)-N-methylfuran-2-carboxamide
   Show/Hide
C17H16N8O2
 1
1 IC50 = 150 nM
CP0204448
N-[1-(4-amino-6-methyl-1,3,5-triazin-2-yl)benzimidazol-2-yl]-1,2-oxazol-3-amine
   Show/Hide
C14H12N8O
 1
1 IC50 = 150 nM
CP0669285
US8552004, 2.03
   Show/Hide
C21H27N7O2S
 1
1 IC50 = 150 nM
CP0050333
3-(1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)benzamide
   Show/Hide
C18H16N8O
 1
1 IC50 = 175 nM
CP0305075
CHEMBL1945794
   Show/Hide
C18H19N5O3
 1
1 IC50 = 178 nM
CP0267910
CHEMBL1945793
   Show/Hide
C18H19N5O3
 1
1 IC50 = 179 nM
CP0102640
4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)pyrimidin-4-yl]morpholine
   Show/Hide
C20H22N4O3S
 1
1 IC50 = 180 nM
CP0050332
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1H-pyrazol-4-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C14H13N9
 1
1 IC50 = 190 nM
CP0205211
3-(cyclohexylmethyl)-5-(1H-indazol-5-yl)-1H-imidazo[4,5-b]pyrazin-2-one
   Show/Hide
C19H20N6O
 1
1 IC50 = 190 nM
CP0157307
4-[2-(1H-indol-4-yl)-6-(2-methylsulfonylpropan-2-yl)pyrimidin-4-yl]morpholine
   Show/Hide
C20H24N4O3S
 1
1 IC50 = 190 nM
CP0096185
pyrazolo pyrimidine, 5a
   Show/Hide
C20H24N6O2
 1
1 IC50 = 215 nM
CP0076974
4-[2-(1H-indol-4-yl)-6-(4-methylsulfonylpiperidin-4-yl)pyrimidin-4-yl]morpholine
   Show/Hide
C22H27N5O3S
 1
1 IC50 = 230 nM
CP0314463
3-(1-(4-(methylamino)-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C17H15N7O
 1
1 IC50 = 250 nM
CP0204363
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1-methyl-1H-pyrazol-3-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C15H15N9
 1
1 IC50 = 270 nM
CP0142926
N-[3-[[1-(4-amino-6-methyl-1,3,5-triazin-2-yl)benzimidazol-2-yl]amino]phenyl]acetamide
   Show/Hide
C19H18N8O
 1
1 IC50 = 290 nM
CP0085620
4-[2-(1H-indol-4-yl)-6-(methylsulfonylmethyl)pyrimidin-4-yl]morpholine
   Show/Hide
C18H20N4O3S
 1
1 IC50 = 330 nM
CP0050329
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C15H13F2N9
 1
1 IC50 = 340 nM
CP0297677
3-(1-(2-methylpyrimidin-4-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C18H15N5O
 1
1 IC50 = 370 nM
CP0808811
CERALASERTIB
   Show/Hide
C20H24N6O2S
 1
1 IC50 = 370 nM
CP0204360
3-(1-(4-amino-6-ethyl-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C18H17N7O
 1
1 IC50 = 390 nM
CP0219214
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-phenyl-1H-benzo[d]imidazol-2-amine
   Show/Hide
C17H15N7
 1
1 IC50 = 420 nM
CP0168095
(3-(9-(1-benzylpiperidin-4-yl)-6-morpholino-9H-purin-2-yl)phenyl)methanol
   Show/Hide
C28H32N6O2
 2
1 IC50 = 634 nM
2 IC50 = 1000 nM
CP0107926
3-(6-morpholino-9-(piperidin-4-yl)-9H-purin-2-yl)phenol
   Show/Hide
C20H24N6O2
 1
1 IC50 = 950 nM
CP0002420
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
   Show/Hide
C19H17NO3
 9
1 IC50 = 1060 nM
2 IC50 = 2500 nM
3 IC50 = 2800 nM
4 IC50 = 3018 nM
5 IC50 = 3900 nM
6 IC50 = 5000 nM
7 IC50 = 6796 nM
8 IC50 = 9900 nM
9 IC50 > 10000 nM
CP0674735
(E)-4-((2-(4,6-dimorpholino-1,3,5-triazin-2-yl)hydrazono)methyl)-2,6-dimethoxyphenol
   Show/Hide
C20H27N7O5
 1
1 IC50 = 1370 nM
CP0008405
(2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
   Show/Hide
C19H22F3N5O2S
 2
1 IC50 = 1461 nM
2 IC50 > 9100 nM
CP0240345
3-(6-morpholino-9H-purin-2-yl)phenol
   Show/Hide
C15H15N5O2
 1
1 IC50 = 1650 nM
CP0378452
[(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
   Show/Hide
C56H87NO16
 1
1 IC50 = 2290 nM
CP0050327
3-(1-(4-(phenylamino)-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C22H17N7O
 1
1 IC50 = 2300 nM
CP0219140
3-(1-(1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C16H12N6O
 1
1 IC50 = 3000 nM
CP0204361
3-(1-(4-amino-6-propyl-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C19H19N7O
 1
1 IC50 = 4700 nM
CP0163043
4-((1H-Indazol-3-yl)ethynyl)aniline
   Show/Hide
C15H11N3
 1
1 IC50 = 4970 nM
CP0053313
3-(Pyridin-2-ylethynyl)-1H-pyrazolo[3,4-b]pyridine
   Show/Hide
C13H8N4
 1
1 IC50 = 5000 nM
CP0022970
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one
   Show/Hide
C16H15N3O2
 1
1 IC50 = 5300 nM
CP0016546
2-(morpholin-4-yl)-benzo[h]chromen-4-one
   Show/Hide
C17H15NO3
 1
1 IC50 = 6400 nM
CP0128358
(3-(6-morpholino-9-(piperidin-4-yl)-9H-purin-2-yl)phenyl)methanol
   Show/Hide
C21H26N6O2
 1
1 IC50 = 7200 nM
CP0025862
3-(Pyridin-4-ylethynyl)-1H-indazole
   Show/Hide
C14H9N3
 1
1 IC50 = 10700 nM
CP0204359
3-(1-(4-(pyridin-2-ylmethylamino)-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C22H18N8O
 1
1 IC50 = 21000 nM
CP0050334
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C16H19N7O
 1
1 IC50 = 21400 nM
CP0287663
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C13H12N10
 1
1 IC50 = 33100 nM
CP0045578
3-(Pyridin-4-ylethynyl)-1H-pyrazolo[3,4-b]pyridine
   Show/Hide
C13H8N4
 1
1 IC50 > 10000 nM
CP0137572
2-(4-(2-(3-hydroxyphenylamino)-1H-benzo[d]imidazol-1-yl)-6-methoxy-1,3,5-triazin-2-ylamino)acetonitrile
   Show/Hide
C19H16N8O2
 1
1 IC50 > 50000 nM
CP0160282
1-(4-amino-6-methyl-1,3,5-triazin-2-yl)-N-(1-methyl-1H-pyrazol-5-yl)-1H-benzo[d]imidazol-2-amine
   Show/Hide
C15H15N9
 1
1 IC50 > 50000 nM
CP0169967
3-(1-(4-methoxy-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C17H14N6O2
 1
1 IC50 > 50000 nM
CP0314464
3-(1-(4-(2,2,2-trifluoroethylamino)-1,3,5-triazin-2-yl)-1H-benzo[d]imidazol-2-ylamino)phenol
   Show/Hide
C18H14F3N7O
 1
1 IC50 > 50000 nM
CP0045572
3-(Phenylethynyl)-1H-indazole
   Show/Hide
C15H10N2
 1
1 IC50 > 100000 nM
CP0053294
3-(1H-Indazol-3-yl)-N,N-dimethylprop-2-yn-1-amine
   Show/Hide
C12H13N3
 1
1 IC50 > 100000 nM
CP0053314
3-((3,5-Bis(trifluoromethyl)phenyl)ethynyl)-1Hindazole
   Show/Hide
C17H8F6N2
 1
1 IC50 > 100000 nM
CP0055412
3-((1H-Indazol-3-yl)ethynyl)aniline
   Show/Hide
C15H11N3
 1
1 IC50 > 100000 nM
CP0083593
3-(Pyridin-3-ylethynyl)-1H-indazole
   Show/Hide
C14H9N3
 1
1 IC50 > 100000 nM
CP0124812
3-(Pyridin-2-ylethynyl)-1H-indazole
   Show/Hide
C14H9N3
 1
1 IC50 > 100000 nM
CP0135085
3-(Cyclopropylethynyl)-1H-indazole
   Show/Hide
C12H10N2
 1
1 IC50 > 100000 nM
CP0163046
3-(Cyclopentylethynyl)-1H-indazole
   Show/Hide
C14H14N2
 1
1 IC50 > 100000 nM
CP0242179
3-(Thiophen-3-ylethynyl)-1H-indazole
   Show/Hide
C13H8N2S
 1
1 IC50 > 100000 nM
CP0296504
2-((1H-Indazol-3-yl)ethynyl)aniline
   Show/Hide
C15H11N3
 1
1 IC50 > 100000 nM
CP0319910
4-((1H-Indazol-3-yl)ethynyl)benzonitrile
   Show/Hide
C16H9N3
 1
1 IC50 > 100000 nM
Clinical Information about the Protein
Target 1 ( Serine/threonine-protein kinase mTOR (mTOR) )
Target Type Successful Target
Disease 11 Target-related Diseases  11
1 Renal cell carcinoma [ICD-11: 2C90]
2 Chronic myelomonocytic leukaemia [ICD-11: 2A40]
3 Organ transplant rejection [ICD-11: NE84]
4 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
5 Sarcoma [ICD-11: 2A60-2C35]
6 Non-hodgkin lymphoma [ICD-11: 2B33.5]
7 Breast cancer [ICD-11: 2C60-2C65]
8 Squamous head and neck cell carcinom [ICD-11: 2D60.0]
9 Head and neck cancer [ICD-11: 2D42]
10 Lung cancer [ICD-11: 2C25.0]
11 T-cell leukaemia [ICD-11: 2A90]
Approved Drug(s) 5 Approved Drugs  5
1 Everolimus Approved
Renal cell carcinoma
2 PF-04449913 Approved
Chronic myelomonocytic leukaemia
3 Sirolimus Approved
Organ transplant rejection
4 Temsirolimus Approved
Renal cell carcinoma
5 Zotarolimus Approved
Solid tumour/cancer
Clinical Trial Drug(s) 13 Clinical Trial Drugs  13
1 Ridaforolimus Phase 3
Sarcoma
2 AZD2014 Phase 2
Solid tumour/cancer
3 BEZ235 Phase 2
Solid tumour/cancer
4 PF-05212384 Phase 2
Solid tumour/cancer
5 BGT226 Phase 1/2
Solid tumour/cancer
6 GDC-0349 Phase 1
Non-hodgkin lymphoma
7 GDC-0980/RG7422 Phase 2
Non-hodgkin lymphoma
8 INK128 Phase 2
Breast cancer
9 PQR309 Phase 2
Squamous head and neck cell carcinom
10 SAR245409 Phase 2
Solid tumour/cancer
11 SF1126 Phase 2
Head and neck cancer
12 Salirasib Phase 2
Lung cancer
13 VS-5584 Phase 1
Solid tumour/cancer
Discontinued Drug(s) 1 Discontinued Drug  1
1 AZD8055 Discontinued in Phase 1/2
Solid tumour/cancer
Investigative Drug(s) 2 Investigative Drugs  2
1 EM-101 Investigative
Solid tumour/cancer
2 Torin2 Investigative
T-cell leukaemia
Target 2 ( HUMAN mammalian target of rapamycin (mTOR) )
Target Type Unknown Type Target
Disease 3 Target-related Diseases  3
1 Advanced/metastatic breast cancer [ICD-11: 2C60]
2 Lymphangioleiomyomatosis [ICD-11: CB07]
3 Breast cancer [ICD-11: 2C60-2C65]
Clinical Trial Drug(s) 1 Clinical Trial Drug  1
1 Sirolimus Approved
Lymphangioleiomyomatosis
Investigative Drug(s) 3 Investigative Drugs  3
1 Everolimus Approved
Advanced/metastatic breast cancer
2 Rapamycin Approved
Lymphangioleiomyomatosis
3 Sapanisertib Phase 2
Breast cancer
Similar Protein(s) and Bioactivity Statistics
90% Identity
Protein ID Protein Name Protein Organism
PT02733 Serine/threonine-protein kinase mTOR Mus musculus, Mouse